News and Announcements
Proteomics Appoints New Non-Executive Director
- Published October 14, 2016 2:57PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
14th October 2016, ASX Announcement
Life sciences company Proteomics International Laboratories Ltd (PILL, ASX: PIQ) is delighted to announce the appointment of Mr Roger Moore as a Non-Executive Director of the Company.
The appointment brings key industry and sector experience to the Board as the Company seeks to commercialise its lead diagnostics product, PromarkerD, and expand its analytical services in Asia.
Roger Moore has 40 years experience in the international pharmaceutical industry, including almost 30 years as President of Novo Nordisk Japan (Novo Nordisk is the world’s largest manufacturer of insulin and a global leader in diabetes care). Mr Moore established Novo’s organisation in Japan as the first employee in 1977, and worked for the company until his retirement as Chairman at the end of 2007. From 2000, Roger Moore was appointed Senior Vice President, Japan and Oceania Region, responsible for Novo Nordisk’s business in Japan, Australia, New Zealand and the Pacific. He was also appointed a member of the Senior Management Board, Novo Nordisk A/S.
To view the full announcement, please click on the button below.